Inogen Company Profile (NASDAQ:INGN)

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen, Inc (NASDAQ:INGN) issued its quarterly earnings results on Thursday, August, 3rd. The company reported $0.38 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.10. The business had revenue of $64.10 million for the quarter, compared to analysts' expectations of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The business's quarterly revenue was up 17.4% on a year-over-year basis. During the same period last year, the business earned $0.25 earnings per share. View Inogen's Earnings History.

4 equities research analysts have issued twelve-month price targets for Inogen's shares. Their forecasts range from $75.00 to $108.00. On average, they expect Inogen's stock price to reach $91.00 in the next twelve months. View Analyst Ratings for Inogen.

Here are some recent quotes from research analysts about Inogen stock:

• 1. According to Zacks Investment Research, "Inogen reported a stellar second quarter of 2017, beating the Zacks Consensus Estimate for both the counts. Solid domestic and international business-to-business sales drove revenues. In fact, the company expects direct-to-consumer sales to be its fastest growing channel, followed by domestic business-to-business sales in the coming quarters, with solid focus in Europe. Inogen recently signed a lease for its expansion site in Ohio to accelerate growth in domestic direct-to-consumer sales channel. The company took a series of strategic initiatives to strengthen its product offerings and market position. On the flip side, declining rental revenues raise concern. Moreover, since the company generates a significant portion of its revenues from the international market, volatile foreign exchange rate will continue to raise concern. Over the last three months, Inogen has outperformed the broader industry in terms of price." (8/8/2017)
• 2. Needham & Company LLC analysts commented, "INGN beat consensus revenue, EBITDA, and EPS in 1Q17. Management maintained its 2017 revenue and EBITDA guidance and raised its 2017 net income guidance. The revenue upside was driven by 49% growth in B2B more than offsetting 0% growth in DTC. We think that the strong 84% growth in domestic B2B provides further evidence that home medical equipment companies (HMEs) are increasingly adopting portable oxygen concentrators." (5/10/2017)
• 3. Stifel Nicolaus analysts commented, "Inogen (INGN) reported 4Q16 after the close on February 28, 2017 with results better than our expectations. Revenue, Adjusted-EBITDA, and Net Income all exceeded our expectations. Management slightly raised its recently established 2017 guidance. In our view, INGN has a great longer-term story that should continue to evolve and grow as disruption occurs in the high cost delivery model of oxygen to those that need it. Maintain Hold and adjust target to $65 based on a range of valuation multiples." (3/1/2017)

Some companies that are related to Inogen include ICU Medical (ICUI), NuVasive (NUVA), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), OraSure Technologies (OSUR), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), Asante Solutions (PUMP), Intersect ENT (XENT), Orthofix International N.V. (OFIX), AtriCure (ATRC), CryoLife (CRY) and Landauer (LDR).

Inogen's management team includes the folowing people:

• Heath Lukatch Ph.D., Independent Chairman of the Board
• Scott Wilkinson, President, Chief Executive Officer, Director
• Alison Bauerlein, Executive Vice President - Finance and Chief Financial Officer, Corporate Secretary and Corporate Treasurer
• Byron Myers, Executive Vice President of Sales and Marketing
• Matthew Scribner, Executive Vice President - Operations
• Brenton Taylor, Executive Vice President - Engineering
• Benjamin M. Anderson-Ray, Independent Director
• Scott A. Beardsley, Independent Director
• R. Scott Greer, Independent Director
• Raymond O. Huggenberger, Independent Director

Inogen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.45%), Vanguard Group Inc. (7.36%), Blair William & Co. IL (4.16%), Koch Industries Inc. (3.17%), Dimensional Fund Advisors LP (2.52%) and TimesSquare Capital Management LLC (2.43%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

Inogen's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Peregrine Capital Management LLC, TimesSquare Capital Management LLC, Blair William & Co. IL, Royce & Associates LP, Osterweis Capital Management Inc., Public Employees Retirement System of Ohio and Wells Fargo & Company MN. Company insiders that have sold Inogen stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.

Inogen's stock was acquired by a variety of institutional investors in the last quarter, including Koch Industries Inc., Vanguard Group Inc., New York State Common Retirement Fund, Russell Investments Group Ltd., Goldman Sachs Group Inc., Marshall Wace North America L.P., Ameriprise Financial Inc. and Kennedy Capital Management Inc.. View Insider Buying and Selling for Inogen.

Shares of Inogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Inogen stock can currently be purchased for approximately $93.96.